

Simplify diabetes care for your Type 1 and Type 2 patients!

With the Omnipod DASH® Insulin Management System

Omnipod DASH® is a two-part **insulin delivery system** consisting of a wireless, smart-phone-like device and a wearable Pod that provides insulin delivery, offering a simple and freeing alternative to multiple daily injections and tethered tubed pumps.

Patient Type

Cleared for use for the management of diabetes mellitus in persons requiring insulin.

Insulin Choice

U-100 short-acting insulin used for both basal and bolus doses. Fiasp®, Novolog®, Humalog®, Apidra®, Admelog®, and Lyumjev® are cleared for use within the Pod.

Insurance Status

Widely covered as a **pharmacy benefit** across commercial and Medicare Part D insurers and select Medicaid Programs, for over 235 million lives and counting. If pharmacy coverage is denied, medical coverage may be available.

HOW TO PROCESS THE SCRIPTS

Omnipod DASH® Pods (Gen 4) Refill 5-Pack

- NDC 08508-2000-05
- Prescribed and filled to patient insulin requirements:
 - **2 boxes/month** = 30-day supply for a 72-hour change-out
 - **3 boxes/month** = 30-day supply for a 48-hour change-out



Personal Diabetes Manager (PDM)


- Supplied by Insulet, maker of Omnipod DASH®.
- PDM is **FREE of charge** with the first box of Pods!

Training: Required for new users either virtually or in-person (*individualized setup*). New users to contact Omnipod® at **1-800-591-3455** or visit **omnipod.com/training** to schedule their training.

THE POD

- Tubeless, wearable, waterproof², disposable insulin delivery device.
- Provides up to 72 hours of continuous insulin direct-to-subcutaneous-tissue.

Pod shown without the necessary adhesive.



THE PDM (Controller)

- Touchscreen Personal Diabetes Manager communicates with the Pod using Bluetooth® wireless technology.
- Intuitive interface with built-in food library³ and Spanish language option.
- Mobile apps available to expand patient's care team with remote access to actionable data.
- Powered by a rechargeable lithium-ion battery.

HOW OMNIPOD DASH® WORKS




1 Fill it up.

Pod contains a 200-unit insulin reservoir*. Once filled, it automatically primes itself and performs a series of safety checks.



2 Stick it on.

Pod can be placed almost anywhere the patient would give themselves an injection. The cannula (a small tube) inserts automatically.



3 Start it up.

PDM controls the delivery of insulin with just a few taps of an intuitive touchscreen controller.

*Insulin not included with Pod

ANTICIPATED PHARMACY BENEFITS

Increased Therapy Adherence⁴ • Enhanced Patient Satisfaction⁵

DEMONSTRATED PATIENT BENEFITS

Simplified Therapy • Greater Quality of Life⁶
Reduced Diabetes Distress⁷

To learn more about Omnipod DASH®, visit omnipod.com

Insulet Corporation • 100 Nagog Park, Acton, MA 01720 • 800-591-3455

1. Data on file: Omnipod DASH® System customers will be eligible to receive one FREE PDM every four years with the purchase of Pods subject to certain conditions including, but not limited to, verification of insurance. 2. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. 3. Food library available in the English language only. 4. 74% of HCPs believe that the Omnipod DASH® System improves adherence to pump therapy among Type 1 and Type 2 patients switching from MDI. Based on the HCPs survey, conducted in November 2020. 140 HCPs were surveyed to gauge the practical experience of Omnipod DASH® System use. Seagrove Partners, LLC, 2020. 5. Among new Omnipod® customers, 92% are satisfied or very satisfied. Data on file. This study was completed on a prior generation of the Omnipod® Insulin Management System. 6. 53.5% of patients reported a net improvement in general well-being. This study was completed on a prior generation of the Omnipod® Insulin Management System. Adapted from Polonsky WH, et al. 1245 patients (>18 years) with Type 1 diabetes completed an online questionnaire examining perceived changes in QoL and glycemic control since Omnipod® System initiation. 56% of patients were on MDI prior to Omnipod®, 44%—on another pump. Study conducted in the USA. Polonsky WH, et al. Diabetes Technol Ther. 2016 Oct;18(10):664-670. 7. In a survey with 1246 adults with T1D, approximately 70% of Omnipod® System users reported a positive decrease (change) in diabetes distress after 6-24 months of Pod. This study was done on a prior generation of the Omnipod® System.

© 2021 Insulet Corporation. Omnipod, the Omnipod logo, DASH, and the DASH logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Insulet Corporation is under license. INS-ODS-11-2021-00087 V2.0

